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5-AMINOSALICYLIC ACID (5-ASA) has been used for over
50 years in the treatment of inflammatory bowel disease
in the pro-drug form sulphasalazine (SASP). SASP is also
used to treat rheumatoid arthritis. However whether the
therapeutic properties of SASP are due to the intact mole-
cule, the 5-ASA or sulphapyridine components is un-
known. Several mechanisms of action have been proposed
for 5-ASA and SASP including interference in the metabol-
ism of arachidonic acid to prostaglandins and leuko-
trienes, scavenging,of reactive oxygen species, effects on
leucocyte function and production of cytokines. However,
it is unlikely that the anti-inflammatory properties ofSASP
and 5-ASA are due to several different properties but more
likely that a single property of 5-ASA explains the thera-
apeutic effects of 5-ASA and SASP. Reactive oxygen
species (ROS) are involved in the metabolism of prosta-
glandins and leukotrienes and can act as second messen-
gers, and so the scavenging of ROS may be the single
mechanism of action of 5-ASA that gives rise to its anti-
inflammatory effects in both inflammatory bowel disease
and rheumatoid arthritis.
Key words: 5-Aminosalicylic acid, Inflammatory bowel dis-
ease, Reactive oxygen species, Rheumatoid arthritis, Sulpha-
salazine
Mechanism of action of
5-arninosalicylic acid
N. A. Punchard,cA S. M. Greenfield and
R. P. H. Thompson
Gastrointestinal Laboratory, The Rayne Institute,
St Thomas’ Hospital, London SE1 7EH, UK
CA Corresponding Author
Introduction
Although corticosteroids are the major anti-
inflammatory agents used to treat the chronic
inflammatory conditions rheumatoid arthritis (RA)
and inflammatory bowel disease (IBD), another
useful agent is the salicylate derivative 5-
aminosalicylic acid (5-ASA). 5-ASA has been used
for over half a century in the pro-drug form
sulphasalazine (SASP) to treat ulcerative colitis
(UC), but was originally designed for use in RA, in
which, until relatively recently, it has not been
widely used. More recently, SASP has also been
used in the treatment of mild psoriasis.
In the late 1930s Dr Nanna Svartz of the
Karolinska Institute, Stockholm, became interested
in treating RA, believed then to be due to an
infectious agent, with the recently developed
anti-bacterial agents, the sulphonamides, which
were beneficial in the treatment of septic arthritis.
2
However, treatment with these agents either alone
or in conjunction with salicylates, which were
already used to treat RA, proved ineffective. As
salicylate drugs reduced the swelling in inflamed
joints but had a lesser effect in reducing
inflammation elsewhere in the body it was possible
that they became concentrated in the joints, and
thus Dr Svartz had the concept that if the salicylate
was bound to the sulphonamide then the salicylate
(C) 1992 Rapid Communications of Oxford ktd
might carry it into the joint, where it would be
antibacterial. Dr Svartz therefore tried to bond
salicylic acid chemically to sulphapyridine, but
without success.
However, as a result of a chance meeting she
convinced Pharmacia in Stockholm to help
2 and in
collaboration with their chemists, E. Askelof and
Dr P. H. Willstaedt, a variety of different combina-
tions of salicylate and sulphonamide were pro-
duced. One of these, salicylazosulphapyridine, more
commonly referred to as sulphasalazine (SASP) and
consisting of 5-aminosalicylic acid (5-ASA) and
sulphapyridine (SP) joined together by a diazo
bond, proved to be effective in treating RA.
In collaboration with Sture Helander, SASP was
shown to have an affinity for connective and elastic
tissue, such as in the joint capsules and in the bowel,
to the extent of forming deposits that gradually
broke down to produce 5-ASA and SP. 3-5 As in UC
the inflammatory changes occurred in the sub-
epithelial connective tissue and as SP had been used
with moderate success by Dr Svartz in the treatment
of UC, which was then also believed to be due to
an infectious agent,
6,v she treated UC patients with
SASP and found that "some cases which did not
become free of symptoms with sulphapyridine
rapidly improved with salazopyrine".
6
However, the Second World War and the
development of more effective gold based drugs in
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the treatment of RA
8 retarded the use of SASP in
UC and RA. It was therefore not until the early
1950s that SASP was used in the USA9 and the UK,
and in 1963 the first controlled, double-blind trials
showed SASP to be effective in the treatment of
mild UC,
1 and later in maintaining remission of
UC.
1 In the 1970s its use for RA was rediscovered
2
and confirmed in a series of studies.
3
In 1977 direct application of the components of
SASP to the colonic mucosa in patients with acute
UC demonstrated that 5-ASA, but not SP,
produced remission in UC similar to that achieved
with SASP, TM as confirmed in other studies,15’6 and
that SP was relatively inactive.
17 Thus it is now
considered that in the treatment of UC the SASP
acts as a pro-drug, with SP acting as a carrier,
delivering the active moiety, 5-ASA, to the inflamed
colon. The realization that 5-ASA is the active
moiety and that the SP component is responsible
for the side effects of SASP, such as infertility,
haemolytic anaemia, photosensitization and agranu-
locytosis, has led to the development of new
preparations of 5-ASA. These consist of 5-ASA
alone, either covered by a pH sensitive coating or
as slow release microgranules that break down in
the colon, or of 5-ASA bound to an inactive carrier
molecule or to another molecule of 5-ASA by an
azo bond (azodisalicylic acid) that, as for SASP, is
broken down by bacteria releasing the 5-ASA in
the bowel. The main use of 5-ASA in IBD is in
UC, although it has some benet in the
treatment of patients with the IBD Crohn’s disease
(CD).
In RA, although some studies have indicated that
SP may be the active moiety
18-21 due to a
bacteriostatic effect, others show that SP on its own
is ineffective
22 and it has been suggested that the
intact SASP molecule may possess anti-inflamma-
tory properties.
23-25 The ability of SASP to
accumulate in connective tissues of the joints where
it is broken down to release 5-ASA, raises the
possibility that SASP may act also as a pro-drug in
RA, but delivering 5-ASA, the active component,
to the inflamed joint where it is slowly released.
The lack of effect of oral 5-ASA in RA can be
explained on the basis of its rapid metabolism and
excretion once absorbed from the gastrointestinal
tract.
Despite its use for over 50 years, the mechanism
of action of SASP and 5-ASA remains unclear. A
large number of studies have lead to a wide range
of hypotheses. This review will attempt to relate
the effects of SASP and 5-ASA on production of
biological mediators to their effects on cells and
tissues, and to those of nonsteroidal anti-
inflammatory agents, but is mainly concerned with
the proposed mechanisms of action in IBD, from
which comes most of the information available.
152 Mediators of Inflammation Vol 1992
Arachidonic Acid Metabolism
Enzymatic oxidation of the essential fatty acid
arachidonic acid gives rise to three main groups of
compounds: the prostaglandins (PGs) and throm-
boxanes (TXs) produced by the cyclooxygenase
pathway; the leukotrienes (LTs) and the inter-
mediate hydroxyeicosatetraenoic acids (HETEs)
from the lipoxygenase pathway; and another group,
the lipoxins. The lipoxins have not been studied
with respect to SASP and 5-ASA. The products of
arachidonic acid are rapidly turned over, locally
acting mediators that have been implicated in a
range of physiological procedures including re-
production, inflammation, immunological re-
sponses and cell growth, division, motility and
transport processes.
The cyclooxygenase pathway: Early studies indicated that
some PGs, for example prostaglandin E2 (PGE2)
were proinflammatory. Thus the increased levels
found at sites of inflammation or in samples derived
from inflamed sites, and the increased PG
production by leucocytes from patients with
chronic inflammatory diseases all supported this.
Raised concentrations of prostaglandins in the
stools of patients with active UC were first
described by Gould
6 and subsequently increased
concentrations of PGE2 were found in rectal
mucosal biopsy specimens,
27-3 stools2’ and rectal
dialysates of UC patients
4-3 with active disease,
suggesting that the increased PGs were associated
with generation of the inflammation in IBD. The
non-steroidal anti-inflammatory agents (NSAIDs)
are considered to act through inhibition of the
cyclooxygenase pathway, and so increased PG
production by the inflamed bowel on removal
of SASP treatment or decreased production with
SASP27’28’34’36 or 5-ASA5’ suggested that the
mechanism of action of SASP and 5-ASA was also
through inhibition of the cyclooxygenase enzyme.
Earlier in vitro studies supported this, but later




that relatively low concentrations of SASP and/or
5-ASA can enhance PG production with inhibition
of PG production mainly only occurring at high
concentrations. Even in some studies in which PG
production was only inhibited, promotion can be
observed either as a negative inhibition41 or by a
dose related, but not significant, enhancement.4
Although SP enhanced production of one out of
four PGs measured in one study,
4 in the others,
either in cell free incubations,33’4’43’47’48 or in
incubations of gastrointestinal biopsies27’3 or
mononuclear (MN) cells,
38 SP either had no
effect33’36’40’48 or inhibited2"’30’31’38’39’41’47’49 PG pro-
duction, dose dependently.
8
Except in one study where 5-ASA actuallyMechanism of action of 5-ASA
Table 1. In vitro studies of the effects of sulphasalazine on prostaglandin and thromboxane production
Study Tissue studied Concentration Effects on
mol I- cyclooxygenase
products
Collier et al.; 197647
Smith et al.; 197827
Sharon et al.; 197831
Hoult & Moore; 197849
Hoult & Moore; 198048
Ligumsky et al.; 198130
Gould et al.; 198133
Schlenker & Peskar; 198152
Rachmilewitz et al. 198240
Hawkey & Trulove; 198341
Stenson & Lobos; 198342
Hawkey et al.; 198543
Kolassa et al.; 198545
Hillier et al.; 1984TM
Keating et al.; 198846
Punchard et al.; 199238
Bull seminal vesical IC5o 4.7 x 10-4 $(E2 4- F2)
#
homogenates
Human normal and 0.2-50 x 10-4 ,(I 2 4- F2
inflamed mucosal homogenates
Human normal and 2.5 x 10-4 ,E2
inflamed rectal biopsies
Rat colonic microsomes 10-8-10-3 E2
Animal microsomal preparation 0.1 & 10-3 ,(E2 4- F2
Human normal and inflamed 2.52 10-4 12, E2, TXA2
rectal biopsies
Rat fundus strip 0.2-2 10-3 SPG
(indirect bioassay)
Human colon mucosal 2.5 x 10-4 1"E2
microsomes
Unstimulated PBMNC from 1.26 & 2.52 x 10-4 NA.
healthy subjects 5 x 10-4 (1’a) E2, TXA2
Colitic rectal biopsy 10-6 & 10-4, 1’52
homogenates O-3_10 2 $E2
Platelets 0.1-4.0 x 10-3 1"E2, 1"F2, TXA2
Human colonic mucosal 5 10-5 12, E2, 1’F2=, TXA2
homogenates 10-3 $12, E2, 1"F2=, TXA2
Rabbit colonic microsomes 10-3 NA on 12, E2, F2, TXA2
Stimulated PBMNC 1.26 10-4 1"E2
Stimulated PBMNC from (not quoted) 1"E2
BD patients
PBMNC from healthy subjects;
Unstimulated 10-7-10-5 NA
10-4 1"12, 1"E2, 1"F2
10-3 12, 1"E2, F2
LPS-stimulated 10-7 & 10-6 NA
10-5 & 10-4 1"12, 1"E2, 1"F2=
10-3 ,12, E2, ,F2
E2--Prostaglandin PGE2; F2= PGF2; 12 PGI2; TXA2 Thromboxane A2; PBMNC peripheral blood mononuclear
cells.
In these studies PGI 2 and TXA were measured as their respective stable hydrolysis products 6KFI and TXB2.
no effect; enhancement; inhibition. NA no effect on any PGs measured, as opposed to those PGs measured
as stated which were effected.
# In this study the sum of both PGs was reported.
Enhancement in this study was not significant but as it is large and increased with increasing concentration of drug we
have included it.
In this study results are presented as % inhibition and this enhancement is apparent as negative (<0%) inhibition which
is reduced with increasing concentration to produce inhibition at high concentrations.
d In this study whether PG production was enhanced or inhibited depended on the concentration of substrate used.
All concentrations have been converted to mol 1-1 to allow direct comparison.
enhanced production, both SASP and 5-ASA
inhibit production of thromboxane A2 (TXA2) a
potent vasoconstrictor that increases the adhesion
to the endothelium and aggregation of platelets and
polymorphonuclear cells (PMN). SP either in-
hibits3’4’41 or has no effect42 on TXA2 production.
Although inhibition of TXA2 production by SASP
is associated with increased PG production,42’5
inhibition of TXA2 synthesis by 5-ASA
42 and
specific TXA2 inhibitors42’s is not, suggesting that
the promotion of PGs is not just a result of
inhibition of TXA2 synthesis increasing the
availability of substrate. However, the converse,
that increased synthesis of PGs removes substrate
for TXA2 synthesis, may be true. In a model of
colitis 5-ASA and inhibitors of TXA2 were equally
effective anti-inflammatory agents, suggesting that
the anti-inflammatory properties might be through
inhibition of TXA2 production.
51
Differences in the incubation conditions used
may alter the responses of the tissues to the drugs
and this may be why 5-ASA and SASP inhibit PG
production in some studies and, at the same
concentration, enhance production in others. For
example, in one study the concentration of the
exogenous substrate (arachidonic acid) determined
whether SASP enhanced or inhibited PGE2
production,
s2 while in another addition of substrate
reversed the inhibition of MN cell PG production
by SASP.
s3 We have also found that stimulation of
MN cells increases their sensitivity to the effects of
SASP, 5-ASA and SP, which may result from
increased concentrations of free arachidonic acid
released by phospholipases activated by stimulation
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Table 2. In vitro studies of the effects of 5-aminosalicylic acid on prostaglandin and thromboxane production





Collier et al.; 197647
Sharon et al.; 197831
Hoult & Moore; 198048
Hoult & Page; 198139
Ligumsky et al." 198130
Gould et al." 198133
Rachmilewitz et al. 19824o
Hawkey & Trulove; 198341
Stenson & Lobos; 198342
Hawkey et al.; 198543
Berry & Hoult; 198444
Kolassa et al.; 198545
Keating et al.; 198849
Mahida et al.; 1991138
Punchard et al." 199238
Bull seminal vesical
homogenates






















PBMNC from healthy subjects:
Unstimulated
LPS-stimulated
IC5o 7.1 x 10-3 $(E2 4- F2)
#
3.2 x 10-4 E2
0.1 & x 10-3 J,(E2 4- F2)
5 & 50 x 10-5 1"12, 1"F2=
5 X 10-3 NA
5 x 10-5 NA
5 X 10 --4 1"12, 1"F2
5 x 10-3 J,12, F2=
3.2 x 10-3 ,1,12, J, E2, TXA2
6.5 x 10-4 12, E2, ,I,TXA2
1.3 x 10-3 ,I,12, ,I, E2, STXA2
0.1-10 x 10-3 ,I,PG
3.3 x 10-5 NA
3.3 x 10-4 ,I, E2, TXA2
4.9 & 32.7 x 10-4 E2, TXA2
10-5 10-3 E2
10--3-10 -1 $E2
0.1-4.0 x 10-3 E2, F2, STXA2
5 x 10-5 NA
x 10-3 12, $E2, F2, TXA2
5 x 10-4 1"12,
> 5 x 10-4 12
10-5 1"12, E2, F2, I"TXA2
10-4 1"12, 1"E2, F2, TTXA2
10-3 1"12, 1"E2, TF2, TTXA2
(not quoted) TE2
3.3 & 6.6 x 10 -4 TXA2
10 -7, 10 -6, 10 -5, 10-4 NA
10-3 ,12, ,E2, F2
10 -.7 NA
10-6 12, 1"E2, 1"F2=
10-5 12, E2, 1"F2
10-4 NA
10-3 12, E2, ,F2=
E2--Prostaglandin PGE2; F2= PGF2; 12--PGI2; TXA2= Thromboxane A2; PBMNC peripheral blood mononuclear
cells.
In these studies PGI 2 and TXA2 were measured as their respective stable hydrolysis products 6KFI and TXB 2.
no effect; 1’ enhancement; inhibition. NA no effect on any PGs measured, as opposed to those PGs measured
as stated which were effected.
# In this study the sum of both PGs was reported.
Enhancement in this study was not significant but as it is large and increased with increasing concentration of drug we
have included it.
In this study results are presented as % inhibition and this enhancement is apparent as negative (<0%) inhibition which
is reduced with increasing concentration to produce inhibition at high concentrations.
d In this study whether PG production was enhanced or inhibited depended on the concentration of substrate used.
All concentrations have been converted to mol I-1 to allow direct comparison.
with LPS. The increase in production ofPG by MN
cells from healthy subjects with 5-ASA38’s4 is much
less than that found using MN cells from IBD
patients.
46 This may indicate that cells from IBD
patients are more sensitive to 5-ASA, possibly due
to prior activation by the inflammatory process
in vivo. Some in vitro incubations may thus have used
relative proportions of SASP, substrate and enzyme
that only favoured inhibition. The conversion of
added radiolabelled arachidonic acid to PGs, as used
in some studies, may not have mimicked the
unlabelled endogenous substrate and a low
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conversion substrate could even result from
increased competition and conversion of en-
dogenous substrate.
There is indeed little evidence that SASP and
5-ASA inhibit PG synthesis in patients. In some
studies PG production in vivo in patients who
relapsed during maintenance therapy with SASP
increased despite treatment
34 and in patients treated
with 5-ASA but who failed to respond to therapy
PG levels increased,
37 suggesting that disease
activity rather than treatment produces the changes
in PG production. Removal of SASP therapy inMechanism of action of 5-ASA
patients with inactive disease did not affect
production,ss The in vivo and ex vivo changes
observed in patients associated with SASP or
5-ASA therapy may equally have been due to a
reduction in the numbers of PG-producing cells in
the bow.el, specifically the mononuclear cells (MN)
since polymorphonuclear cells produce little or no
PG. s6 The degree of inflammatory cell infiltrate in
animalsss’sv and the increased levels of the substrate
arachidonic acid in the mucosa in IBD
s8 have been
correlated with the cell density of the inflammatory
infiltrate
s9 and thus changes in PG production may
be the secondary consequence of the. invasion of the
inflamed bowel by MN cells.
28 Changes in
permeability with inflammation could also lead to
increased leakage of PGs into the bowel. Thus it is
likely that the decrease in PG production associated
with SASP reflects only a decrease in the number
of PG-producing MN cells present in the colonic
mucosa during the healing process.
Indomethacin and other (NSAIDs) are far more
potent inhibitors of PG production than either
SASP or 5-ASA and are not effective in the
treatment of, and may even exacerbate, UC.
6-64
Moreover, not only can PGs and their analogues
protect the gastric and small intestinal mucosa
against injury (cytoprotection) but they are also
protective in the colon.
6s-69 Production of PGs may
therefore be beneficial rather than damaging. A
failure to produce protective PGs in response to
stimulation in the inflamed bowel may exacerbate
the disease and be important in maintaining the
inflammatory process. However, in RA NSAIDs
are beneficial. This would suggest that either there
are different mechanisms involved in the inflamma-
tion in RA, that the site of the inflammation
modifies the action of the drugs, or that the effects
of NSAIDs are not directly related to their actions
on the cyclooxygenase enzyme.
The promotion of PG production with low
concentrations of 5-ASA may" be because 5-ASA,
acting as an antioxidant and reducing co-factor,
prevents free radical mediated inactivation of
cyclooxygenase. 39’44 Similarly, SASP (see below)
can also act as an antioxidant and could thus also
act as a reducing co-factor in PG synthesis.
Conversely, the inhibition ofPG production at high
concentrations of SASP and 5-ASA may be due to
inactivation of cyclooxygenase by free radical
intermediates of the drug.v Other antioxidants can
also affect PG synthesis,
7>76 and thus some of the
inconsistencies between previous in vitro studies
may be due either to the addition to the incubation
media of the antioxidants adrenaline and reduced
glutathione,27’4’47 both of which affect PG produc-
tion,4’42’49’72 or to losses of endogenous antioxidants
during preparation of the homogenates.
77
SASP inhibits the NAD-dependent 15-hydroxy
PG dehydrogenases (NAD-PGDH), which are
enzymes that catabolize PGs to their 15-keto-13,14
dihydro derivatives, in cell free systems,48’49’v8-8 the
isolated perfused rat lung
48 and when perfused into
rats.48 NSAIDs such as indomethacin, which are
ineffective or deleterious in IBD, also inhibit
NAD.-PGDH non-competitively,48’w’8-82 although
unlike SASP, they are more active as inhibitors of
PG synthesis than breakdown.49’ However,
NAD-PGDH is unstable under conditions similar
to those used in most of the above in vitro studies81
and the inhibition of PGDH by indomethacin is
through formation of an unreactive complex and
denaturation of the NADH enzyme in vitro rather
than a phenomenon of physiological import-
ance.1’2 It is recommended that inhibition of
PGDH observed in aqueous solutions should be
confirmed under conditions such that denaturation
or itlactivation would not occur.8’82 Such studies
have not been performed with SASP and thus it is
unclear whether SASP inhibits or simply inactivates
NAD-PGDH. Other types ofPGDH with different
specificities for the different PGs, higher reactivity
with cofactors other than NAD,
83 and broad
substrate specificities
s4 have been described and it
is unclear whether SASP has the same effects on all
of these.
The human lung is less sensitive to SASP than
the.rats and the high concentrations of SASP used
and removal of the effects of SASP upon the
addition of albumin to the perfusate suggests that
SASP in the circulation will have little effect upon
PG degradation in vivo. It is possible that SASP,
rather than acting inside tissues, blocks PG
uptake.s’6 The unphysiologically high concentra-
tions of PGs and SASP used, and lack of
information on the changes in endogenous,
unlabelled pools in some of these studies also raises
doubts about the interpretation of the results. When
PG synthesis and catabolism have been measured
together, inhibition of PG catabolism by SASP is
not associated with increased production4s’49 or
production of both the PG and its metabolite are
enhanced simultaneously,
s2 Furthermore 5-ASA,
and also SP, were not active as inhibitors of the
NAD-PGDH.48,78,79
Whether SASP and 5-ASA inhibit or enhance
MN cell PG production in vitro also depends on the
compound, its concentration, which PG is being
measured, and whether PG production is stimulated
or not. The species of animal used also alters the
inhibition ofPG production by SASP and 5-ASA.48
The incubation conditions affect the results seen,
and so whether the conditions in the mucosa are
accurately reproduced in cell and tissue incubations
is unknown. The results from such in vitro studies
should therefore be extrapolated to the therapeutic
mechanisms in vivo with caution.
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Whereas the concentrations of these drugs in the
bowel lumen could favour either enhancement or
inhibition of PG production, they are probably
much lower in the mucosa where they are likely to
enhance PG production. The enhancement of PG
production by SASP and 5-ASA, with mainly
inhibition by the clinically ineffective SP, and the
cytoprotective et:fects of PGs all suggest that
enhancement is a more likely mechanism of action
of SASP and 5-ASA than inhibition. Thus SASP
and 5-ASA could act therapeutically in IBD by
enhancing protective PG production either alone,
or together with inhibition of pro-inflammatory
products of arachidonic acid.
SASP is poorly absorbed in the colon, and is
unlikely to have systemic effects on PG degradation.
5-ASA has little, if any, eflect on PGDH48’78’79 and
thus inhibition of PG degradation is unlikely to be
the mechanism of action of 5-ASA in IBD. SP also
inhibits PG production and the PG-inhibiting
NSAIDs are ineffective in IBD, thus inhibition of
PG production also seems unlikely as a mechanism
of action in IBD. That SP also inhibits TXA2
production and yet is ineffective in IBD may
suggest that this is also an unlikely mechanism.
Whether this is also true in RA depends upon which
component of SASP is the active ingredient and
whether NSAIDs possess other anti-inflammatory
properties besides inhibition of PG production.
Whether the mechanism by which 5-ASA and SASP
promote PG production in vitro is the same or
different is not certain, but given that PGs are
protective to the colon, promotion of PG
production by 5-ASA could explain the therapeutic
properties of 5-ASA and the lack of effectiveness of
SP in IBD. Whether promotion of PGs could also
be protective in RA is unknown and it is possible
that SASP and 5-ASA possess other properties that
explain their anti-inflammatory effects in RA.
Lipoxygenase products: Much of the cellular damage at
sites of inflammation is due to the local actions of
activated leucocytes at the inflamed site. The
increased recruitment of leucocytes from the
peripheral blood into the inflamed site is in part a
result of increased production of potent chemotac-
tic lipoxygenase products, for example 5-HETE
and LTB4. The anti-inflammatory effects of SASP
and 5-ASA could thus be through reducing
leucocyte recruitment into the inflamed bowel by
inhibiting production of these chemotactic agents.
In cell free systems 5-ASA,87’88 but not SP,
86
inhibits soyabean lipoxygenase activity, but there
is disagreement as to whether SASP does or does
not,
89 probably a result of dit:ferent analytical
methods being used in the two studies. In cells both
SASP and 5-ASA inhibit the production of HETEs
by PMN
9-93 and also sulphidopeptide leukotrienes
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by rat peritoneal cells,
94 but in platelets both these
drugs enhance 12-HETE production.
42 SP has
either a weak
93 or no effect on the lipoxygenase
pathway.42’8"’94 SASP inhibits production of
HETEs by inflamed mucosa in vitro,43’94 and both
SASP and 5-ASA inhibit synthesis of LTB4 and
sulphidopeptide leukotrienes by both normal and
inflamed mucosa9-98 and in rat basophil leukaemia
cells,
99 probably through inhibition of glutathione
transferase.
99 Although 5-ASA inhibited production
of HETEs by inflamed mucosa in vitro in one
study, it did not in another.4 Similarly, although
acetyl 5-ASA was as good an inhibitor of soyabean
lipoxygenase as 5-ASA,sv other studies show acetyl
5-ASA to have no effect on PMN lipoxygenase
activity. 91’92 It is possible that the methods used for
determining the activity of the lipoxygenase
pathway or, as for PG production, diflerences in
the incubation conditions may alter the result
obtained, suggesting that these in vitro results
should be correlated to the in vivo situation with
caution.
The promotion of PG production, for example
as observed in our MN cell incubations,s could
have been due to inhibition of the lipoxygenase
pathway and redirecting of substrate into prosta-
glandin synthesis. However, 5-ASA or SASP did
not affect MN cell LTB4 production when PG
synthesis was enhanced
46 and inhibition of the
lipoxygenase pathway was not associated with
increased cyclooxygenase activity. 95’9v
How closely these in vitro studies are related to
the clinical mechanism of 5-ASA and SASP is
unclear. Acetyl 5-ASA does not aect IBD, and yet
in one study was as good an inhibitor of soyabean
lipoxygenase as 5-ASA.
8v Conversely, 4-ASA, as
effective as 5-ASA in the treatment of UC, does not
inhibit PMN lipoxygenase activity in vitro.
9 A
5-1ipoxygenase inhibitor was as effective as 5-ASA
in a rat model of colitis1 and yet benoxaprofen, a
putative lipoxygenase inhibitor, was ineffective in
UC. Although increased levels of LTB4 occur in
the inflamed bowel,
95 the concentrations of LTB4
in the colonic lumen were unchanged during
successful 5-ASA treatment of patients with IBD.
37
As for PG production, the changes that occur in
LTB4 production with remission induced either by
a lipoxygenase inhibitor or 5-ASA in an animal
model of colitis were concluded to be due more to
a reduction in the numbers of PMN, the major
source of LTB4, infiltrating the bowel than due to
a direct effect on the lipoxygenase pathway.
An action of 5-ASA and SASP as lipoxygenase
inhibitors would explain the clinical effects of these
drugs in IBD and RA and the ineffectiveness of SP.
However, although lipoxygenase inhibitors reduce
LTB4 production in UC
2 they still have to be
shown to benefit IBD and RA. Many of theMechanism of action of 5-ASA
products of the lipoxygenase pathway resemble
those generated through non-enzymic attack of
arachidonic acid by reactive oxygen species (ROS),
while ROS are generated in the lipoxygenase
pathway. Thus it may be difficult to differentiate
between an effect of SASP and 5-ASA as ROS
scavengers and an effect as inhibitors of the
lipoxygenase pathway.
Reactive Oxygen Species
Reactive oxygen species (ROS) are forms of
oxygen that are more strongly oxidizing than
oxygen itself, and include hydrogen peroxide
(H202) lipid peroxides, hypochlorous acid (HOCl)
and oxygen-free radical species such as the
superoxide and hydroxyl free radicals. Their ability
to react with cellular constituents, resulting in
damage to proteins, nucleic acids and cell
membranes, means that ROS are highly toxic to
living systems. Their reactive nature also means that
ROS react with molecules close to their origin, the
distance migrated being directly proportional to
their reactivity. The ability of antioxidants to
prevent cellular damage at sites of inflammation and
ischaemia suggest that the ROS produced in these
situations play an important role in generating the
tissue injury.
At sites of inflammation the major source of the
ROS are activated PMN, although MN cells also
produce ROS. Activated PMN produce anti-
microbial and cytotoxic ROS, namely the super-
oxide radical and -I202 and, through the action of
the enzyme myeloperoxidase (MPO) on H202 and
the chloride ion, release HOC1. The ROS released
may also react with suitable transition metals to
produce the highly reactive hydroxyl radical. In
addition, HOC1 inactivates alpha-l-protease, which
protects tissues against proteolysis at inflamed sites,
and activates collagenase released from PMN. Some
of the damage in IBD and RA is also suggested to
arise from ischaemia. During periods of ischaemia
ATP is broken down to hypoxanthine, and the
enzyme xanthine dehydrogenase is converted to
xanthine oxidase (XOD), which, upon reperfusion
of the tissues, utilizes the oxygen to metabolize the
hypoxanthine and in so doing generates the
superoxide radical. Furthermore, changes in the
endothelium promote PMN endothelial interac-
tions, leading to activation of the PMN and a
subsequent burst of ROS production from the
PMN.
In cell free systems SASP, 5-ASA and SP all
scavenge the hydroxyl radical equally, with rate
constants close to the diffusion controlled limits.12
The products of the attack of 5-ASA by ROS from
stimulated leucocytes are similar to those produced
by the iron-mediated Fenton reaction and are
indicative of a reaction between 5-ASA and the
hydroxyl radical.I4 However, neither 5-ASA, SASP
nor SP aEected hydroxyl radical production in a
xanthine oxidase cell free system,
15 and only
5-ASA, out of the three, inhibited the eEects of
hydroxyl radical production by PMN suggesting
that under some conditions the eEects of SASP and
its metabolites may be negligible. Although the
ability of 5-ASA to scavenge the hydroxyl radical
in vitro may not reflect an ability to act as a hydroxyl
radical scavenger in IBD,
*6 5-ASA is as eective as
the hydroxyl radical scavenger dimethylsulphoxide
(DMSO) in preventing experimentally induced
ischaemia/reperfusion gastric injury.
17
The effects of 5-ASA on the hydroxyl radical may
be less important in IBD than the effects on
leucocyte MPO-derived HOC1.18 In a cell free
system 5-ASA and SP both inhibited MPO-
generated HOC1 and had a direct inhibitory effect
on the MPO enzyme.
9 SASP inhibits the metabolic
burst ofPMN that fuels the MPO,
1 and SASP and
5-ASA could act as inhibitors of the MPO enzyme
rather than as scavengers of the ROS produced by
MPO. Certainly the methods used for detecting
ROS in cells often do not distinguish between
inhibition of ROS production and scavenging
effects. However, others have found inhibition of
PMN ROS by SASP and 5-ASA not to be
associated with decreased oxygen consumptionS* ’112
and the products ofROS attack of 5-ASA are found
in leucocyte incubations,
14 indicating that inhibi-
tion of ROS activity by scavenging does occur in
some incubations.
When formyl-methionyl-leucyl-phenylalanine
(f-mlp) is used to stimulate PMN, 5-ASA and
SASP’13 and SP13 all inhibit MPO dependent
chemiluminescence. However, when phorbyl myri-
state acetate (PMA) has been used to stimulate
PMN neither 5-ASA SASP11’1 nor SP
affected, chemiluminescence. This lack of effect may
either be because the intracellular site of ROS
generated by PMA stimulation is inaccessible to the
drugs
11 or to a lack of eect of the drugs against
ROS produced by mechanisms that are independent
of intracellular calcium release, suggesting that the
eects of SASP and 5-ASA are calcium de-
pendent.
1 Thus the effects of SASP and 5-ASA on
PMN ROS generation depend on the stimulant
used.
However, in other studies 5-ASA was an effective
inhibitor of MPO activity in PMA-stimulated
PMN
2 and in zymosan-stimulated PMN 5-ASA,
but not SP, inhibited chemiluminescence.s How-
ever, SP was a better inhibitor of MPO
induced iodination than 5-ASA.
114 SASP was
inactive in both studies.sJ4 In cell free systems SP
and 5-ASA inhibited MPO by different mechan-
isms.
4 Although in one study 5-ASA, but not
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SASP nor SP, eectively inhibited production of
the superoxide radical by PMN,
ls yet conversely,
SASP and SP, but not 5-ASA inhibited the activity
in another.TM Differences in incubation conditions
and methodology may modify the eect of 5-ASA
and SASP on ROS in vitro and account for the
differences between these studies.
The ability of SASP and diazosalicylic acid to
inhibit the activity of the superoxide radical
produced by PMN and to inhibit oxygen uptake by
the cells, whereas SP was relatively inactive,
suggest that this results from direct inhibition of
the enzymes.
1 In the same study SASP and
diazosalicylic acid inhibited the activity of XOD-
generated superoxide and urate production suggest-
ing that again they acted directly on the XOD
enzyme and not on the ROS produced.
1 This may
be due to the diazo bond, rather than the 5-ASA
structure, found in both molecules, since in a cell
free system SASP, but not SP nor 5-ASA, inhibited
XOD-generated superoxide activity,
ls Conversely,
in another cell free study both 5-ASA and SASP
reduced the activity of XOD generated superoxide
radical and thus might equally be due to the 5-ASA
component.
115 However, in this latter study uric
acid production was not altered suggesting that the
result was due to a scavenging effect rather than
inhibition of the XOD enzyme. It is thus unclear
whether in addition to scavenging PMN ROS,
SASP and 5-ASA may also inhibit the enzymes
involved in their production in vitro.
5-ASA and SASP also inhibit the action of
peroxides. 5-ASA, and to a lesser extent SASP but
not SP, reduce the activity of H202 produced by
PMN and xanthine oxidase,ls Furthermore, we
have shown that 5-ASA, and to a lesser extent
SASP, but SP only marginally, inhibit production
of lipid peroxides in ROS stressed erythrocytes,54’11
and others that 5-ASA is more effective than SASP,
diazosalicylic acid or SP in inhibiting haemoglobin
catalysed lipid peroxidation,
lv In other studies
5-ASA, but not SASP nor SP, scavenged (reduced)
the organic radical 1,1-diphenyl-2-picrylhydra-
zyl,92’118 and thus the anti-inflammatory effects of
5-ASA may be directed at other, organic radical
species. 5-ASA, but not SASP nor SP, also protects
the protein, alpha-l-antiprotease against inactiva-
tion by HOC1.
3
The ability of 5-ASA and SASP to react with
ROS with sufficient affinity enables them to protect
cellular constituents against ROS-mediated injury
as illustrated by the ability of 5-ASA to protect cells
in culture against the superoxide radical and H202
TM
and also stimulated PMN.
112 Moreover, in a cellular
system 5-ASA and SASP, but not SP, also reduced
ROS-induced chemiluminescence in colonic muco-
sal scrapings, and reduced cytochrome C reduction
by colonic crypt cells.s This suggests that
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scavenging of ROS may be more important than
any effect on the enzymes involved in their
generation.
The ROS scavenging ability of 5-ASA and SASP
may be the basis of their anti-inflammatory
properties. SASP reduced inflammation in acetic
acid induced colitis in an animal model as effectively
as did superoxide scavengers.
119 The iron chelator
desferrioxamine was without effect
ll9 and thus it is
unlikely that the action of SASP and 5-ASA is
through binding to ROS generating transition
metals.
6 As bothXOD inhibitors andDMSO have
limited effectiveness in this model, HOC1 rather
than the hydroxyl or XOD, was the probable target
of the scavenging properties of SASP.
9 However,
both 5-ASA and DMSO were anti-inflammatory in
a model of ischaemia/reperfusion induced gastric
injury, suggesting that 5-ASA was an effective
hydroxyl radical scavenger,
lv 5-ASA and SASP,
but not SP, protected the bowel against both XOD
and bile acid induced ROS damage
115 and also in
an experimental model of acute ileitis in rats
induced by perfusion of f-mlp where PMN-
generated ROS give rise to cellular damage.
19 It
would thus appear that the ability of SASP and
5-ASA to react with a wide range of ROS allows
them to protect against the damage due to the
different ROS produced in different circumstances.
SASP, but not 5-ASA, prevent NSAID gen-
erated inflammation,
19 which is also reduced or
abolished by free radical scavengers in animals. The
lack of effect of 5-ASA in this model was suggested
to be due to rapid inactivation of 5-ASA when
given orally.
2 Moreover, whereas SASP and
5-ASA, but not SP, directly infused into the colon
prevents the bile acid induced loss of DNA and
increased cellular turnover, the NSAID in-
domethacin increased it.
115 Although NSAIDs also
scavenge ROS,121’122 which may account for some
of their anti-inflammatory properties, the reaction
with ROS may also generate toxic free radical
derivatives of the NSAIDs,
123 hence the ability of
other antioxidants to suppress the toxicity of
NSAIDs in vivo. However, there is no evidence that
the products of the reaction between ROS and
5-ASA and SASP are toxic, and SASP, like other
antioxidants, protects against NSAID damage
in vivo.
The above studies suggest a role for SASP and
5-ASA as scavengers of ROS. Although in vitro they
may also have a direct effect on the enzymes
producing the ROS in the inflamed bowel it is
unlikely that, in vivo, they will be absorbed in
sufficiently high enough concentrations for this
effect to exceed their scavenging properties. Thus
the antioxidant effects of SASP and 5-ASA are a
more likely anti-inflammatory mechanism of action.
The lack of effect of SP as a ROS scavenger in mostMechanism of action of 5-ASA
systems is consistent with its lack of therapeutic Whether NK activity is lower127 or higher
12s in
properties in IBD. Differences observed between IBD is unclear and in one study neither SASP
some studies may be a result of methodological nor SP inhibited NK activity in vitro. The
differences altering the effects of SASP and 5-ASA, disparity between the therapeutic efficacy of
for example in one study 5-ASA could not be tested SASP and its metabolites and their effects on NK
because it directly reacted with the cytochrome C.11 activity in vitro suggests that NK activity is not a
Although the products of the reaction between major pathogenic mechanism in UC
2s for 5-ASA
5-ASA and ROS have been found in faeces of is the active molecule in IBD and yet has no
patients with IBD, supporting the concept that effect on NK activity. Although the effects of
5-ASA reacts with ROS in IBD,
23 convincing SASP on NK activity are not relevant to IBD,
evidence that the ability of 5-ASA and SASP to act whether they are relevant in RA depends on
as scavengers of ROS is the basis of their anti- whether the intact SASP molecule is the active
inflammatory propertiesisstilllacking. Attemptsto therapeutic moiety, and on the role of NK
correlate changes in ROS production at sites of activity in RA.
inflammation with antioxidant effects will be
dicult for, as for PG and leukotriene production, Suppressor cell activity" Inflammation is a balance
changes seen may be more a reflection of changes between pro-inflammatory and anti-inflammatory
in numbers of leucocytes present.
23 Nevertheless, aspects of the immune system. The anti-inflam-
if SASP and 5-ASA can be shown to act as matory properties of SASP and 5-ASA could re-
scavengers of ROS in IBD and RA, then other sult from an effect on MN cells, such as inhibition
drugs that are potential antioxidants may also be of antibody synthesis or modification oflymphocyte
beneficial in RA and IBD.24 suppressor or helper cell function leading to
down-regulation and suppression of the pro-
inflammatory aspects of the immune system.
2-25
Cellular and Tissue Effects This is supported by inhibition of mitogen-
stimulatedMN cell antibody secretion by SASP and
Natural killer (NK) cell activity" A population of 5-ASA,
9 and proliferation by SASP22’23’12s’129
the MN cells that is toxic to epithelial cells has been in vitro. 5-ASA also inhibited mitogen-induced
identified with the same phenotype as natural expression of cell surface activation markers,
3 but
killer (NK) cells,
2s suggesting that cell mediated although 5-ASA inhibited mitogen-induced prolif-
cytotoxicity by NK cells contributes to the eration in some studies129’3 but in others it was
cellular injury in IBD.
26 Thus a possible inactive.23’2s’32 SP also had no effect on MN cell
mechanism of action of SASP and 5-ASA could antibody production
33 or proliferation,23as’129’132
be through inhibition of NK cell activity, even when added with 5-ASA suggesting that the
SASP and SP inhibited in vitro cell mediated intact SASP molecule is the active moiety,
is
cytotoxicity by peripheral blood MN cells and Conflictingly, in one study SASP, 5-ASA and SP
SASP by intestinal MN cells,
26 while SASP all inhibited mitogen-induced activation of MN
therapy reduced ex vivo NK cell activity in IBD cells from healthy subjects and RA patients in vitro
patients.
127 However, 5-ASA in in vitro incuba- suggesting that the metabolites of SASP could also
tions, 125’126’128 or in vivo when given to patients,
2 be active under some conditions.24 The effects seen
has little effect on NK activity, and thus the effects differed with the mitogen used,
24 and it is possible
of SASP may be due to the SP component.
26 that differences in the studies above are a result of
Alternatively, they may be due to the diazo bond different mitogens being used.
of SASP since azodisalicylic, that shares with SASP The effects of SASP on induction of a suppressor
the possession of a diazo bond, also inhibits NK cell function might be through effects on PGs,
activity,
is and may thus be a property of the intact which have been implicated in the regulation of
SASP molecule. The eects of SASP on NK cell suppressor cell activity. Although co-administra-
activity may be indirect, through effects on tion ofindomethacin with SASP caused a reduction
production ofcytokines, but are unlikely to involve in the effects of SASP on mitogen induced
the cyclooxygenase pathway as indomethacin had activation in one study,
129 it did not in
no effect on NK activity at concentrations required others. 129’132’133 Thus it is unclear whether PGs are
to inhibit cyclooxygenase. 125’26 SP accounts for involved. Other cytokines could also be involved.
the toxic effect of SASP in vivo and has toxic SASP and 5-ASAinhibited mitogen activation of
effects in vivo and in vitro on MN cells (as cells from IBD patients more than those from
discussed below). It is thus possible that the healthy subjects,
29 suggesting that such raised
effects on NK cell activity are a toxic action and pro-immunological responses are susceptible to
the low NK activity reported in IBD a result of inhibition. In RA, SASP treatment reduced
drug treatment rather than the disease process.
29 circulating levels of activated lymphocytes and
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abnormal ex vivo lymphocyte responses to mito-
gens.24’135 However, in the latter study the change
occurred only in those who responded to
treatment135 and thus may have been due to a
general reduction in disease activity rather than a
direct effect of SASP.
ls Neither SASP, 5-ASA nor
SP had any effect on suppressor cell activity when
measured directly
16 or on MN cell subpopulations
in vitro or in vivo,
28 and the ability of SASP to inhibit
mitogen stimulation ofMN cells activation may be
due to a toxic eect.
3
SASP could act therapeutically in IBD and RA
by affecting suppressor cell function, with SP being
inactive due to its lack of effect. However, 5-ASA
is largely inactive in this system and yet is the active
component in IBD. Thus if this eect of SASP
occurs in patients, then the therapeutic mechanism
of action of SASP and 5-ASA may be different.
Alternatively, SASP may be toxic to MN cells, as
indicated below and the effects seen in vitro
irrelevant to either IBD or RA.
Toxic effects" The few clinical side effects that SASP
possesses are associated with the SP component,
rather than 5-ASA, although recent studies have
suggested that 5-ASA may be nephrotoxic.
However, in vitro SASP is toxic to MN cells38’2s’
and other cells,
25 and 5-ASA is toxic to MN
cells24’8 and we have shown the toxicity of SASP
and 5-ASA to be dose-dependent.
38 However, other
studies have not found SASP23-25’37 or 5-
ASA125’133’137’38 to be toxic to MN cells, and neither
SASP nor 5-ASA to be toxic to PMN,
93
erythrocytes
37 or mouse spleen cells
2 in vitro.
Additionally 5-ASA was not found to be toxic to
other cells in culture.
39
SASP produces chromosomal damage, namely
sister chromatid exchange and micronuclei, to MN
cells in vivo and in vitro, an effect caused by the SP
component.
14 However, when the toxicity of SP
has been studied neither we
38 nor others have found
SP to be toxic in in vitro incubations of MN
cells,23’24’133’138 PMN
93 or mouse spleen cells,is The
toxic side effect of SP in vivo may be due to a toxic
metabolite rather than SP itself.
3 SASP and 5-ASA
may not be toxic in vivo due to the rapid acetylation
of these compounds once absorbed. Some of the
in vitro toxic side effects of SASP in MN cells could
arise through interference with folate metabol-
ism. 141
The reason why SASP and 5-ASA are toxic in
some studies, but not in others could be due to
differences in the incubation conditions, for
example the length of time the cells are exposed to
the drug. Cell death, leading to lysis and
disintegration of cells, is not detected by techniques
measuring membrane permeability, such as trypan
blue exclusion. The toxic effect at high concentra-
tions of SASP and 5-ASA may indicate more subtle
effects on cellular metabolism at lower concentra-
tion. If the ability of SASP to inhibit mitogen-
stimulated MN cell activation is due to a toxic
effect,
129 then some of the other reported effects of
SASP and 5-ASA on cells in culture may also be a
result of their toxicity.
Thus, SASP and 5-ASA can affect the viability
of cells in culture, suggesting that 5-ASA and SASP
may possess toxic properties in vitro, although there
are inconsistencies between these studies. Reliable
and sensitive measurement of cell viability may
confirm that some of the reported effects of these
drugs are due to their toxicity, rather than being
physiologically relevant.
Other Anti-inflammatory Properties
In addition to those discussed above SASP and
5-ASA possess other properties that might explain
their anti-inflammatory effects in RA and IBD.
These include effects of both 5-ASA and SASP, and
not SP, such as the inhibition of synthesis
of pro-inflammatory platelet activating factor
(PAF),
42 or the inhibition of monocyte-dependent
increases in synthesis of ol.-acid-glycoprotein,
143 an
acute phase protein with anti-inflammatory prop-
erties. Others are properties possessed only by
5-ASA, such as inhibition of IL-lfl production
3
or the reduction of interferon-2 induced expression
of the HLA-DR major histocompatibility complex
on cells.
39 An immunomodulatory function of
SASP is also suggested by its beneficial effects in an
experimental model of autoimmune disease,
44 its
ability to prolong rat cardiac allographs
45 and
suppress rejection of intestinal tumours,
46 mediated
by suppression of antibody synthesis.
14a
SASP,114’147’148 and 5-ASA147’148 and SP
114 all
inhibit leucocyte motility, although in some studies
5-ASA
14 and SP14"z had no effect. SASP, but not
SP, also inhibits release of leucocyte granules’4
that contain various pro-inflammatory agents.
Azodisalicylic acid also inhibited granule release,
whereas 5-ASA is relatively inactive,1’12’14
suggesting that this may be a property of the diazo
bond possessed by the intact SASP. Thus it is
unlikely that this is relevant to clinical effects of
both 5-ASA and SASP.
We have shown SASP to inhibit TNF-induced
adhesion molecule expression on leucocytes,
49
although this may be due to effects on the receptor
for TNF as SASP inhibits the binding of TNF to
its receptor. However, neither 5-ASA nor SP
affects binding of TNF. Further studies on the
effects of 5-ASA and SP on adhesion molecule are
required to determine the mechanism of action of
SASP on adhesion molecule expression. SASP also
inhibits binding of f-mlp to its receptor on
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leucocytes
lsl and thus many of the effects of SASP
in vitro may be through inhibiting activation of cells
by preventing binding of the activating agent.
SASP and 5-ASA are highly soluble in ionic and
hydrophobic environments and it is possible that
they bind to proteins on the surface of cells in a
nonspecific fashion. If this is so then it is unlikely
to be the basis of their action in vivo, given the large
number of possible binding sites and proteins with
which they will come into contact.
SASP may affect other cells besides the
leucocytes. SASP inhibits histamine release from
mast cells,
ls2 and this is suggested to be the basis
of its anti-ulcer effects.
53 Although the effects of
SASP and 5-ASA on platelet TXA242 and PffF
142
production may be due to an effect on platelet
function, 5-ASA had no affect on platelet
aggregation and fibrinolytic activity either in vitro
or ill vivo.
154
There is as yet insufficient information on the
above properties of SASP and 5-ASA to suggest
which might be a likely mechanism of action. The
effects of the drugs above might be indirect and
mediated through effects on production of
cytokines such as PGs or leukotrienes, or
antioxidant effects increasing the stability of cell
membranes.
Summary
The results of the many in vitro and in vivo studies
performed suggest that there are several possible
mechanisms that may explain the anti-inflammatory
properties of SASP and 5-ASA. However, it is more
probable that 5-ASA and SASP act in IBD by a
single mechanism, rather than by several different
mechanisms, and that some of the observations are
erroneous due to artefactual effects, or mis-
interpretation of the results. If 5-ASA is the active
moiety in IBD and RA then the effects seen with
intact SASP molecule are likely to be irrelevant
unless they are due to the 5-ASA component within
the intact molecule. However, if the intact molecule
is the active moiety in RA then SASP and 5-ASA
could act by two different anti-inflammatory
mechanisms, for although 5-ASA is as good as
SASP in the treatment ofIBD it has not been shown
to be better. If SP acted as an anti-inflammatory
agent in RA then it should also do so in the inflamed
bowel, where the concentrations are higher. That
it does not suggests that the only possible
mechanism for SP is as an antibacterial agent in RA.
This may suggest that effects seen with SASP or
5-ASA that are also seen with SP may be artefactual.
The conflicting findings in some of the studies
suggest that the methodology employed in in vitro
studies can affect the results seen.
The result of studies of the effects of SASP and
5-ASA on the inflammatory changes in patients,
either measured ex vivo in studies of cells and tissues
or in vivo, are compounded by the heterogeneous
nature of the patient population, such as drug
treatments and the site and severity of the
inflammation. It is also difficult to determine
whether the measured parameter is due to a direct
action of the drug or secondary to a change in the
activity of the inflammation. As discussed above
with respect to PGs the contribution of the
leucocyte infiltrate in samples of inflamed tissue
used for ex vivo and in vivo studies is often
overlooked, as are the traumatic effects of isolation
and preparation procedures on activation of such
cells. Animal models are useful in studying the
mechanism of action of compounds like 5-ASA, but
they do not mimic chronic IBD. A protective effect
of SASP and 5-ASA in animal models may be
mediated by intervention at one of several points
in the inflammatory process, and an effectiveness
equal to that of other agents does not necessarily
imply a common mechanism. Studies of 5-ASA and
SASP in models of RA are still required to dissect
out the active component of SASP. If 5-ASA and
other compounds act upon mechanisms that are
unique to the origin of IBD then the use of such
models to determine the mechanism of action of
SASP and 5-ASA, and for the development of new
anti-inflammatory agents, may be severely limited.
Another problem in studying the mechanism of
action of 5-ASA and SASP using in vitro models is
the relevant concetration of drug that should be
used. This is important for, as demonstrated with
PG synthesis, opposite results can be obtained using
low concentrations compared to those obtained
using high concentrations. Furthermore the effec-
tive concentrations of 5-ASA and SASP in one
anti-inflammatory mechanism are often different to
those required for another. For example, it has been
suggested that the concentrations achieved of
5-ASA in vivo are not high enough to compete with
biological material for the ROS, the hydroxyl
radical.
6 Which is the relevant concentration is
unknown. There is a rapid gradient of drug
concentration from the bowel lumen to the
perfusing blood, which, due to its poor absorption,
will be much steeper for SASP than 5-ASA.
Moreover, once absorbed the drugs are rapidly
inactivated through acetylation. The high con-
centrations of 5-ASA and SASP that exist in the
bowel lumen are often quoted as justification of the
use of similar high concentrations ill vitro but there
is no evidence that 5-ASA and SASP exert their
therapeutic effect in the bowel lumen. In IBD
although the majority of evidence points to a local
action of 5-ASA this is likely to be sited within the
colonic mucosa where concentrations will be lower.
The effective concentration in RA will be much
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lower due to rapid metabolism of SASP and 5-ASA,
thus implying that high concentrations are not
required for the mechanism of action.
The most relevant concentrations will be those
at the active site and if this is in the interstitial fluid
then it could be relatively high. If it is within a
specific cell type, and at a specific organelle then it
could be much lower. The ability of SASP to
become concentrated in connective tissue where it
is then broken down will also produce relatively
high, but highly localized concentrations of 5-ASA.
The effective concentration will also depend on the
activity of the mechanism against which it is acting.
Relative concentrations and incubation conditions
used in in vitro models are designed more with
regard to the detection system used to measure the
products formed than to reproducing accurately the
in vivo levels. Thus a high concentration of drug
required to have an effect in vitro does not
necessarily indicate that a similarly high concentra-
tion will be required in vivo where the activity of
the system against which the drug is acting may be
much lower. It may thus be more important to
consider the relative concentration of the drug
compared to the activity of potential target system
in vitro to that in vivo, rather than just drug
concentrations.
It is possible that a single property of SASP and
5-ASA explains many of their observed actions. For
instance, SASP and 5-ASA can act as antioxidants
and prevent lipid peroxidation. The production of
PGs also involves ROS and PG synthesis is
activated by low levels of peroxides, but is inhibited
by high levels. Thus 5-ASA and SASP may affect
PG production either by reacting with free radical
intermediates in the cyclooxygenase enzyme or by
altering levels of lipid peroxides. Similarly, the
lipoxygenase pathway involves ROS and the
antioxidant glutathione while many of the products
resemble those produced by inorganic ROS
generated lipid peroxidation. Thus 5-ASA and
SASP could also affect this pathway through their
scavenging properties. ROS have also been
suggested to act as chemical messengers
148 and thus
other effects of SASP and 5-ASA could also be due
to the effects on ROS. The mechanism by which
5-ASA inhibited the myeloperoxidase activity
through scavenging the haemoprotein-associated
radical by acting as an alternative substrate18 is
similar to the effects of 5-ASA in PG synthesis and
thus may be a general property of these compounds
in haem based proteins. This could also explain the
effects of SASP and 5-ASA in haemoglobin-induced
lipid peroxidation.
Lower levels of von Willebrand factor in patients
on SASP156 suggest that SASP and/or 5-ASA have
effects on endothelial cell function in IBD. The early
studies by Dr Svartz and her colleagues showed
SASP to be able to bind to vascular tissues. The
endothelium is also a potent producer of PGs and
ROS and has been demonstrated to affect vascular
PG production and function. The endothelium is
also important in controlling the cellular damage
seen in inflammation and ischaemia/reperfusion
injury. Thus the protective effects of 5-ASA as an
antioxidant might be mediated by the protection of
the endothelium and maintenance of production of
vascular prostacyclin and other protective com-
pounds. In addition 5-ASA and SASP both have
effect on leukotrienes and adhesion molecules which
are both important in the regulation of the
recruitment of leukocytes through the vascular
endothelium and into inflamed sites. Thus whatever
the mechanism the vascular endothelium may be the
possible site of the anti-inflammatory properties of
5-ASA and SASP.
An understanding of the mechanisms of action
of5-ASA and SASP, when eventually obtained, will
be a great asset in the development of new
anti-inflammatory agents and may even lead to a
deeper understanding of the pathogenesis of RA
and IBD. More research is required into the
mechanism of action of SASP and 5-ASA in 1BD
and RA before this can be achieved.
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